New pill aims to slow lung decline in scarring disease
NCT ID NCT07503587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether HSK44459 tablets can slow the decline in lung function for adults with progressive pulmonary fibrosis, a condition where lung scarring worsens over time. About 378 participants will take the drug or a placebo twice daily for 52 weeks. The main goal is to measure changes in forced vital capacity, a key breathing test.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HSK44459 tablets
- What this could lead to
- If it works, this could provide a new treatment option to slow lung function decline in people with progressive pulmonary fibrosis.
- What could go wrong
- This is an early Phase 3 trial, so results are not yet known. The drug may not improve lung function or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Beyond the lungs: the hidden emotional toll of IPF medications
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Tracking lung scarring: new registry aims to map progressive pulmonary fibrosis in china
- Small study tackles nasty side effect of lung drug
- Lung disease study probes hidden environmental triggers